🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If it were a T cell, the human body would reprogram the lineage —to restore the equilibrium. Source: ADVANCES IN ARTIFICIAL INTELLIGENCE: IMPLICATIONS FOR CAPITAL MARKET ACTIVITIES imf.org/-/media/Files/… Image courtesy:IMF #AlgoTrading #ShortInterest #OrderFlow

🔑 $TVGN 📉 Short interest fell 41% in May 📈 D. Boral Capital reaffirmed a “buy” rating with a $10 target on May 27 ⁦⁦✅⁦D. Boral Capital⁩ 📰 Source: MarketBeat (June 1, 2025) 📸 Image courtesy MarketBeat #ShortInterest #MarketUpdate #InstitutionalInsights

Today, the FDA launched Elsa, a generative AI tool designed to help employees—from scientific reviewers to investigators—work more efficiently. This innovative tool modernizes agency functions and leverages AI capabilities to better serve the American people. Elsa in Action ➤

🎉 Tevogen Turns FIVE! 🎉 Five years of bold ideas, breakthrough science, and a belief so strong, it borders on irrational. And we wouldn’t have it any other way. Here’s to the next chapter of innovation, accessibility, and purpose-driven impact. Thank you to everyone who’s been

“Tevogen has the potential to achieve success anywhere they go, because they’re founded by such incredible thinkers,” Michelle Ottey, Ph.D., Global Head of Centers and Labs says. Thank you for the kind words! Follow the link below to see how CIC (Cambridge Innovation Center) (Cambridge Innovation Center)

Tevogen Bio details its AI initiative; Proprietary AI-powered immunotherapy with Microsoft and Databricks Partnerships ow.ly/Jxrk50W3YYM

💬 𝐂𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐂𝐄𝐎 💬 $TVGN #affordable #accessible #celltherapy

❤️🇺🇸

1. $TVGN by the Numbers — Source & Image Courtesy: Financial Times 6/6/25 🟢 ↑ 459.47% increase from the 52-week low of Oct 9, 24 🟢 ↑ 1 YEAR CHANGE: +60.22% 🔴 ↓ Short selling activity: Low Note: The company’s current financial statements do not reflect Tevogen’s wholly owned portfolio

2. $TVGN by the Numbers — Source & Image Courtesy: Nasdaq • #ChartIQ • S&P Global Market Intelligence 6/6/25 $TVGN ↑34.9% over the past 3 months $NDX ↑12.0% | $SPX ↑6.9% | $IXIC ↑10.1% over the same period ➡️ Past performance doesn’t predict the future. This is just one snapshot, but

To clarify — Tevogen AI is a separate business unit of Tevogen, complementary to our biotech division but with a broader scope (beyond drug development). With rapid adoption and the support of U.S. leadership, #ArtificialIntelligence is destined to elevate lives and transform

“We are proud to see Tevogen expand its footprint here in Warren,” said Warren Mayor Lisa Lontai. “This expansion is a testament to the groundbreaking innovation happening right here in Warren, and we are proud to be the home of such an innovative company”. ROI-NJ —

Before boardrooms or breakthroughs, there was a chalkboard… and a physics professor. He taught me to dream one size too big— and that compassion and human connection are what make those dreams possible. I may not see him, but I feel his presence. Heart full of respect, I whisper

🎬 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐁𝐢𝐨 𝐋𝐢𝐯𝐞 𝐟𝐫𝐨𝐦 Nasdaq 𝐌𝐚𝐫𝐤𝐞𝐭𝐒𝐢𝐭𝐞 Dr. Neal Flomenberg, Chief Scientific Officer, and Lori Grosso, Clinical Development Lead, discussed Tevogen Bio's goal of making cytotoxic #Tcell #immunotherapy a #mainstream, outpatient treatment. $TVGN